Literature DB >> 19900593

c-Jun N-terminal kinase (JNK) signaling: recent advances and challenges.

Marie A Bogoyevitch1, Kevin R W Ngoei, Teresa T Zhao, Yvonne Y C Yeap, Dominic C H Ng.   

Abstract

c-Jun N-terminal kinases (JNKs), first characterized as stress-activated members of the mitogen-activated protein kinase (MAPK) family, have become a focus of inhibitor screening strategies following studies that have shown their critical roles in the development of a number of diseases, such as diabetes, neurodegeneration and liver disease. We discuss recent advances in the discovery and development of ATP-competitive and ATP-noncompetitive JNK inhibitors. Because understanding the modes of actions of these inhibitors and improving their properties will rely on a better understanding of JNK structure, JNK catalytic mechanisms and substrates, recent advances in these areas of JNK biochemistry are also considered. In addition, the use of JNK gene knockout animals is continuing to reveal in vivo functions for these kinases, with tissue-specific roles now being dissected with tissue-specific knockouts. These latest advances highlight the many challenges now faced, particularly in the directed targeting of the JNK isoforms in specific tissues. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19900593     DOI: 10.1016/j.bbapap.2009.11.002

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  107 in total

Review 1.  Role of C-Jun N-terminal Kinase in Hepatocellular Carcinoma Development.

Authors:  Juan Wang; Guixiang Tai
Journal:  Target Oncol       Date:  2016-12       Impact factor: 4.493

2.  JNK signaling is needed to tolerate chromosomal instability.

Authors:  Heidi W-S Wong; Zeeshan Shaukat; Jianbin Wang; Robert Saint; Stephen L Gregory
Journal:  Cell Cycle       Date:  2013-12-12       Impact factor: 4.534

3.  The p21-activated kinase, PAK2, is important in the activation of numerous pancreatic acinar cell signaling cascades and in the onset of early pancreatitis events.

Authors:  Bernardo Nuche-Berenguer; Irene Ramos-Álvarez; R T Jensen
Journal:  Biochim Biophys Acta       Date:  2016-02-18

4.  Design and characterization of a potent and selective dual ATP- and substrate-competitive subnanomolar bidentate c-Jun N-terminal kinase (JNK) inhibitor.

Authors:  John L Stebbins; Surya K De; Petra Pavlickova; Vida Chen; Thomas Machleidt; Li-Hsing Chen; Christian Kuntzen; Shinichi Kitada; Michael Karin; Maurizio Pellecchia
Journal:  J Med Chem       Date:  2011-08-23       Impact factor: 7.446

Review 5.  Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress.

Authors:  Ira Tabas; David Ron
Journal:  Nat Cell Biol       Date:  2011-03       Impact factor: 28.824

6.  Inhibition of adrenergic human prostate smooth muscle contraction by the inhibitors of c-Jun N-terminal kinase, SP600125 and BI-78D3.

Authors:  F Strittmatter; S Walther; C Gratzke; J Göttinger; C Beckmann; A Roosen; B Schlenker; P Hedlund; K E Andersson; C G Stief; M Hennenberg
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

Review 7.  JNK signalling in cancer: in need of new, smarter therapeutic targets.

Authors:  Concetta Bubici; Salvatore Papa
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

8.  Anti-Inflammatory Effects and Joint Protection in Collagen-Induced Arthritis after Treatment with IQ-1S, a Selective c-Jun N-Terminal Kinase Inhibitor.

Authors:  Igor A Schepetkin; Liliya N Kirpotina; Deepa Hammaker; Irina Kochetkova; Andrei I Khlebnikov; Sergey A Lyakhov; Gary S Firestein; Mark T Quinn
Journal:  J Pharmacol Exp Ther       Date:  2015-03-17       Impact factor: 4.030

9.  Computational prediction and experimental verification of new MAP kinase docking sites and substrates including Gli transcription factors.

Authors:  Thomas C Whisenant; David T Ho; Ryan W Benz; Jeffrey S Rogers; Robyn M Kaake; Elizabeth A Gordon; Lan Huang; Pierre Baldi; Lee Bardwell
Journal:  PLoS Comput Biol       Date:  2010-08-26       Impact factor: 4.475

10.  Inhibition of c-Jun NH2-terminal kinase stimulates mu opioid receptor expression via p38 MAPK-mediated nuclear NF-κB activation in neuronal and non-neuronal cells.

Authors:  Yadav Wagley; Cheol Kyu Hwang; Hong-Yiou Lin; Angel F Y Kam; Ping-Yee Law; Horace H Loh; Li-Na Wei
Journal:  Biochim Biophys Acta       Date:  2013-02-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.